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Abstract
Background: A theoretical advantage of preoperative therapy in pancreatic adenocarcinoma is that it
facilitates the early treatment of micrometastases and reduces postoperative systemic recurrence.
Methods: Medical records of 309 consecutive patients undergoing resection of adenocarcinoma in the
head of the pancreas were reviewed. Survival was calculated using the Kaplan–Meier method. Associa-
tions between preoperative therapy and patterns of recurrence were determined using chi-squared
analysis.
Results: Preoperative therapy was administered to 108 patients and upfront surgery was performed in
201 patients. Preoperative therapy was associated with a significantly longer median disease-free survival
of 14 months compared with 12 months in patients submitted to upfront surgery (P = 0.035). The rate of
local disease as a component of first site of recurrence was significantly lower with preoperative therapy
(11.3%) than with upfront surgery (22.9%) (P = 0.016). Preoperative therapy was associated with a lower
rate of hepatic metastasis (21.7%) than upfront surgery (34.3%) (P = 0.026). Preoperative therapy did not
affect rates of peritoneal or pulmonary metastasis.
Conclusions: Preoperative therapy for pancreatic cancer was associated with longer disease-free
survival and lower rates of local and hepatic recurrences. These data support the use of preoperative
therapy to reduce systemic and local failures after resection.
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Introduction
Despite improvements in operative mortality after pancreati-
coduodenectomy for pancreatic adenocarcinoma, overall survival
has not improved, and most patients succumb to local and distant
recurrences. Randomized controlled trials of surgical resection
followed by adjuvant therapy demonstrate disease relapse rates of
> 70%,1,2 and autopsy series of patients after resection show local
and distant failure rates of 75% and 88%, respectively.3,4 The
potential advantages of preoperative therapy in pancreatic cancer
include improvements in the selection of patients for surgery, and
the achievement of higher rates of negative-margin (R0) resection
and early treatment of micrometastases.5,6 Retrospective reports
show lower local recurrence rates with preoperative therapy com-
pared with adjuvant treatment.7,8 The impact of preoperative
therapy on distant metastases is not well defined. Recent animal
and mathematical model studies suggest that most patients
harbour disseminated disease at the time of diagnosis of pancre-
atic cancer and benefit from early systemic treatment before sur-
gical resection.9,10
The aim of this study was to determine the impact of preopera-
tive therapy on postoperative patterns of recurrence. A retrospec-
tive reviewwas performed of 309 patients submitted to resection of
adenocarcinoma in the head or uncinate process of the pancreas.
Preoperative therapy was associated with significantly lower rates
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of local and hepatic recurrence, but did not affect rates of perito-
neal or pulmonary metastases.
Materials and methods
The medical records of 309 consecutive patients treated for
adenocarcinoma in the head or uncinate process of the pancreas at
Fox Chase Cancer Center (Philadelphia, PA, USA) between Sep-
tember 1990 and November 2009 were reviewed. Pretreatment
evaluation included contrast-enhanced computed tomography
(CT) to assess resectability and exclude metastatic disease. Cyto-
logic tissue diagnosis was obtained by fine needle aspiration under
endoscopic ultrasound or, before the year 2000, CT guidance.
Although preoperative multimodal therapy has been the favoured
treatment strategy for localized pancreatic cancer at Fox Chase
Cancer Center since 1986, many patients were submitted to
surgery first if a tissue diagnosis of malignancy could not be
obtained, if they refused preoperative therapy, if they had under-
gone previous abdominal radiation for an unrelated malignancy,
and at the surgeon’s discretion based on preoperative imaging.
Preoperative regimens were determined by the treating physi-
cians. All patients treated with preoperative therapy received
radiation, usually comprising standard-fractionation 50.4-Gy
external beam radiation with concurrent gemcitabine or
5-fluorouracil (5-FU). If radiographic studies after preoperative
chemoradiation were equivocal for resectability, patients received
full-dose systemic chemotherapy and underwent resection
if restaging scans showed response or stable disease. Patients
receiving additional chemotherapy were treated with 5-FU or
gemcitabine-based regimens.
Resection margins were evaluated systematically as previously
described.11 Tumours were staged after resection according to the
7th edition of the American Joint Committee on Cancer Staging
Manual.12 Postoperatively, patients were evaluated according to
their history and physical examination, serum carbohydrate
antigen 19-9 (CA 19-9) levels, and CT scans of the chest, abdomen
and pelvis every 3–6 months for 3 years, and subsequently
annually.
Local recurrence was defined as disease in the pancreatic bed,
regional nodes and root of the mesentery. Distant recurrence was
defined as disease in the peritoneum outside the pancreatic bed,
malignant ascites, and disease in the liver, lungs or other distant
organs. For the purposes of this study, only first sites of recurrence
were recorded. This study was approved by the Fox Chase Cancer
Center Institutional Review Board, which waived the requirement
for informed consent.
Statistical analysis
Categorical variables were compared using chi-squared analysis.
Continuous data were expressed as the median and range and
compared using the Mann–Whitney test. Survival analysis was
performed using the Kaplan–Meier method, and differences in
survival were compared using the log-rank test. All statistical tests
were two-sided; the significance parameter was set at P < 0.05.
Statistical analysis was performed using spss Version 17.0 (SPSS,
Inc., Chicago, IL, USA).
Results
Patient characteristics
Among the 309 patients who underwent resection of adenocarci-
noma in the pancreatic head or uncinate process, 108 patients
received preoperative therapy and 201 patients underwent surgery
first. Clinicopathologic data are presented in Table 1. In the pre-
operative therapy group, 23 (21.3%) patients received 5-FU-
based chemoradiation and 85 (78.7%) received gemcitabine-based
chemoradiation. Additional preoperative chemotherapy after
chemoradiation was administered in 32 patients (29.6%). In the
surgery-first group, 152 (75.6%) patients received adjuvant 5-FU
or gemcitabine-based regimens, including 125 (62.2%) treated
with radiation as a component of adjuvant therapy. Median
follow-up was 17 months (range: 1–179 months).
Preoperative therapy and patterns of recurrence
Recurrence data were available for 272 patients. The overall recur-
rence rate was 72.8% (198 of 272 patients) during the follow-up
period. Sites of first recurrence are presented in Table 2. Local
recurrence occurred in 12.1% of patients, distant recurrence in
54.4%, and both local and distant recurrence in 6.3%. The most
common sites of distant recurrence were liver, peritoneum and
lung. Multiple sites of first recurrence occurred in 26 (9.6%)
patients.
Preoperative therapy was associated with lower rates of local
and hepatic recurrence, but did not affect rates of peritoneal or
pulmonary metastasis (Fig. 1). Local recurrence occurred in
11.3% (12 of 106) and 22.9% (38 of 166) of patients with and
without preoperative therapy, respectively (P = 0.016). Hepatic
recurrence occurred in 21.7% (23 of 106) and 34.3% (57 of 166)
of patients with and without preoperative therapy, respectively
(P = 0.026). Among patients treated with preoperative therapy,
19.8% (21 of 106) developed peritoneal and/or pulmonary metas-
tases. In patients who underwent surgery first, rates of peritoneal
and pulmonary metastases were 13.9% (23 of 166) and 17.5% (29
of 166), respectively.
Patterns of recurrence and other
clinicopathologic factors
Perineural invasion was significantly associated with the develop-
ment of peritoneal recurrence. Among the 23 patients without
perineural invasion, none developed peritoneal recurrence, com-
pared with 23 of the 142 (16.2%) patients with perineural inva-
sion (P = 0.037). Perineural invasion did not affect rates of local
recurrence, which occurred in 29 of 141 (20.6%) and four of 23
(17.4%) patients with and without perineural invasion, respec-
tively (P = 0.725).
Regional nodal metastases from the primary tumour correlated
with the development of pulmonary metastases, which occurred
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in 23.2% (38 of 164) and 11.1% (12 of 108) of patients with and
without positive lymph nodes, respectively (P = 0.012).
Vascular resection, margin status, T-stage and tumour size did
not correlate with patterns of recurrence. In patients undergoing
surgery first, the receipt of postoperative radiation did not affect
rates of local recurrence.
Survival
Overall survival from the date of diagnosis was 22.0 months [95%
confidence interval (CI) 18.3–25.7] and 18.0 months (95% CI
16.0–20.0) in patients with and without preoperative therapy,
respectively (P = 0.045). When analysed from the date of surgery,
median overall survival was 16.0 months (95% CI 13.2–18.8) and
18.0 months (95% CI 16.2–19.8) in patients with and without
preoperative therapy, respectively (P = 0.700).Median disease-free
survival was 14.0 months (95% CI 11.3–16.7) and 12.0 months
(95% CI 10.4–13.6) in patients with and without preoperative
therapy, respectively (P = 0.035) (Fig. 2).
Median survival from the date of detection of recurrence
was 10.0 months (95% CI 7.3–12.7) in patients with isolated
Table 1 Demographic data for the 309 patients submitted to resection for pancreatic adenocarcinoma
Variable Patients, n (%) P-value
Preoperative therapy
(n = 108)
No preoperative
therapy (n = 201)
Gender, n (%) 0.247
Female 44 (40.7) 118 (58.7)
Male 64 (59.3) 83 (41.3)
Age, years, median (range) 66 (38–84) 67 (35–91) 0.123
Year of diagnosis, n (%) 0.093
1990–2000 41 (38.0) 63 (31.3)
2001–2009 67 (62.0) 138 (68.7)
Postoperative adjuvant therapy, n (%) 48 (44.4) 152 (75.6) <0.001
Preoperative CA 19-9a, U/ml, median (range) 38 (<1–1284) 196 (<1–6928) <0.001
Surgical procedure, n (%) 0.004
Pancreaticoduodenectomy 102 (94.4) 200 (99.5)
Total pancreatectomy 6 (5.6) 1 (0.5)
Vascular resection, n (%) 42 (38.9) 20 (10.0) <0.001
Tumour size, cm, median (range) 2.5 (0–10.5) 3.0 (1.0–8.5) 0.006
Tumour stageb, n (%) <0.001
T0 7 (7.4) 0
T1 11 (11.7) 0
T2 4 (4.3) 4 (2.2)
T3 72 (76.6) 181 (97.8)
Histologic differentiation, n (%) 0.226
Good 4 (3.7) 20 (10.0)
Moderate 28 (25.9) 101 (50.2)
Poor 30 (27.8) 70 (34.8)
Unknown/not determined 46 (42.6) 10 (5.0)
Lymph node metastases, n (%) 36 (33.3) 158 (78.6) <0.001
Perineural invasionc, n (%) 44/62 (71.0) 121/127 (95.3) <0.001
Resection margin, n (%) 0.591
R0 74 (68.5) 126 (62.7)
R1 33 (30.6) 73 (36.3)
R2 1 (0.9) 2 (1.0)
Recurrencec, n (%) 69/106 (65.1) 129/166 (77.7) 0.023
aData available for 90 and 99 patients in the groups treated with and not treated with preoperative therapy, respectively.
bT0, complete pathologic response after preoperative therapy; data available for 94 and 185 patients in the groups treated with and not treated with
preoperative therapy, respectively.
cData not available for all patients, as indicated by denominator.
CA 19-9, carbohydrate antigen 19-9.
36 HPB
HPB 2014, 16, 34–39 © 2013 International Hepato-Pancreato-Biliary Association
pulmonary metastases as the first recurrence, 8.0 months (95% CI
6.3–9.7) in patients with hepatic metastases, 7.0 months (95% CI
6.2–7.8) in patients with local recurrence, and 3.0 months (95%
CI 2.2–3.8) in patients with peritoneal metastases (P < 0.001)
(Fig. 3).
Discussion
The putative benefits of preoperative therapy for pancreatic
adenocarcinoma include early treatment of micrometastases,
higher R0 resection rates, and improved selection of patients for
potentially morbid surgery.5,6 This study evaluated the ability of
preoperative therapy to eradicate micrometastases and its impact
on postoperative patterns of recurrence. Consistent with prior
reports, the most common sites of postoperative disease relapse
were the liver, peritoneum, local sites and lung.13,14 Patients treated
with preoperative therapy had longer disease-free survival and
lower rates of local and hepatic recurrence than patients submit-
ted to upfront surgery. However, preoperative therapy did not
affect overall survival from the date of surgery or the frequency of
peritoneal or pulmonary failures.
Local relapse as a component of first site of recurrence
occurred in 11.3% and 22.9% of patients treated with and
without preoperative therapy, respectively. The lower incidence
of local failure with preoperative therapy in part reflects a sig-
nificant downstaging effect. Although patients treated with
Table 2 Patterns of recurrence in 272 patients
First site(s) of recurrence Patients, n (%)
No recurrence 74 (27.2)
Liver 60 (22.1)
Peritoneum 35 (12.9)
Lung 34 (12.5)
Local 33 (12.1)
Local and liver 7 (2.6)
Liver and lung 6 (2.2)
Bone 5 (1.8)
Othera 18 (6.6)
aIncluding recurrences in the liver and peritoneum (n = 3), malignant
pleural effusion (n = 3), local and peritoneum recurrences (n = 2), local,
liver and lung recurrences (n = 2).
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Figure 1 Sites of first recurrence after pancreatic resection in 272
patients, with (n = 106) and without (n = 166) preoperative therapy
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in 106 patients treated with preoperative therapy than in 166 patients
who underwent immediate surgery (P = 0.035)
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preoperative therapy had locally more advanced tumours, as is
reflected in the higher need in this group for total pancreatec-
tomy and vascular resection, their resected pathologic specimens
exhibited a smaller tumour size, as well as a lower incidence of
positive lymph nodes, and perineural and extrapancreatic inva-
sion. Furthermore, 7.4% of patients treated with preoperative
therapy exhibited a complete pathologic response, which has
been shown to be independently associated with prolonged sur-
vival.15 Other investigators have also demonstrated that preop-
erative therapy is associated with a downstaging effect and lower
local recurrence.7,8
Hepatic metastases as a component of first site of relapse
occurred in 21.7% of patients treated with preoperative therapy,
compared with 34.3% with upfront surgery. Recent in vivo and
mathematical modelling studies demonstrate that most patients
harbour micrometastases at the time of diagnosis of pancreatic
cancer and benefit from therapy that reduces cell proliferation
earlier in the course of treatment.9,10 Amikura et al. calculated
tumour doubling times and observed that radiographically occult
liver metastases are often present at the time of pancreatectomy.16
Thus, the lower incidence of hepatic recurrence with preoperative
therapy is partly attributable to better methods of selecting
patients for surgery which allow the identification of patients with
initially occult micrometastases that become radiographically
evident after preoperative treatment.
Preoperative therapy did not improve rates of peritoneal or
pulmonary recurrence or overall survival from the date of surgery.
Barbier et al. also observed that preoperative therapy did not
result in higher overall survival, despite an improvement in local
control.8 Cytotoxic drug delivery is inefficient in the peritoneal
cavity,17 and gemcitabine and 5-FU may be ineffective in eradicat-
ing pancreatic cancer cells in the peritoneum.
Data on recurrence were available for 272 of the 309 patients,
which highlights the fact that a retrospective review of recurrence
after resection of pancreatic cancer is limited by incomplete radi-
ology and clinician reports. In addition, the present study analysed
first sites(s) of recurrence because many patients do not undergo
further imaging to detect subsequent sites of disease after their
initial diagnosis of recurrence. Other limitations of this study
include its retrospective nature, heterogeneous patient popula-
tion, which included multiple pre- and postoperative chemo-
therapy and chemoradiation regimens, and non-standardized
methods of assessing resectability. Patients were treated before the
recently published consensus statement on definitions of resect-
able and borderline resectable pancreatic cancer.18 In addition, the
present group did not have sufficient data to perform an intent-
to-treat analysis: data on the number of patients who started
preoperative therapy and were not resected were lacking. In early
trials of preoperative therapy in pancreatic cancer, this group
observed resectability rates of between 38% and 67%.19,20
Undoubtedly, patient selection contributed to the improved
disease-free survival after resection in patients who received
preoperative therapy.
In conclusion, preoperative therapy was associated with longer
disease-free survival and lower rates of local and hepatic recur-
rence. Overall survival from the date of pancreatectomy and rates
of pulmonary and peritoneal relapse were not affected by the
receipt of preoperative therapy. In pancreatic adenocarcinoma,
preoperative therapy is recommended to reduce local and hepatic
failures after resection, and improved systemic therapies are
required to control peritoneal and pulmonary recurrences.
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